Using CCDC6 immunostaining in conjunction with the RAD51 HRD assay as a novel approach to expand PARPi treatment eligibility in HGSOC patients
Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, Luca Russolillo, Ilaria De Benedictis, Daniela Califano, Rosaria Catalano, Carmela Baviello, Silvia Varricchio, Sabrina Chiara Cecere, Camilla Nero, Eleonora Palluzzi, Dyonissios Katsaros, E. Capoluongo, Giovanni Luca Scaglione, , Angela Celetti
The paper investigates CCDC6 mutations in HGSOC and shows their link to HRD and PARPi sensitivity, even in BRCA1/2 wild-type patients.
bioRxiv · Jul 29, 2025 · PreprintCancer Biology